approval · primary record
DAPTOMYCIN
4 approval events · latest 2026-09-24
| Agency | FDA |
|---|---|
| Submission type | NDA |
| Latest action | 2026-09-24 |
| Approval events | 4 |
| Brand | DAPTOMYCIN IN 0.9% SODIUM CHLORIDE |
| Sponsor | BAXTER HLTHCARE CORP |
| Route | INTRAVENOUS |
Approval history
4 actions on record. The drug is the stable record; each action below is an event with its own date, so this URL keeps working as new actions arrive.
| Date | Agency | Type | Brand | Sponsor | Route |
|---|---|---|---|---|---|
| 2026-09-24 | FDA | NDA | DAPTOMYCIN IN 0.9% SODIUM CHLORIDE | BAXTER HLTHCARE CORP | INTRAVENOUS |
| 2025-05-12 | FDA | NDA | CUBICIN | CUBIST PHARMS LLC | INTRAVENOUS |
| 2025-04-30 | FDA | NDA | DAPTOMYCIN | HIKMA | INTRAVENOUS |
| 2024-11-21 | FDA | NDA | DAPTOMYCIN | MAIA PHARMS INC | INTRAVENOUS |
Provenance
- Source: openFDA Drugs@FDA
- Fetched at: 2026-10-30T00:27:46.690Z
- Licence class: public-domain
- Verdict: primary-source
- Entity id: approval:daptomycin
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Daptomycin · compound